IP Library Granted Patent US 7,097,835
Granted Patent B2
US 7,097,835 · App. 10/198,003 · Granted Aug 29, 2006

Immunoselective targeting agents and methods of use thereof

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,097,835
App. No.
10/198,003
Granted
Aug 29, 2006
Kind
B2
Abstract

The present invention provides immunoselective targeting agents that bind to transporters that are transiently accessible on the surface of neuronal cells, and that deliver compounds selectively to such cells. The invention provides methods of selectively killing, as well as methods of selectively promoting survival of, a neuronal cell.

Claims (13)

1. An immunotoxin comprising a cytotoxin conjugated to an antibody that specifically binds a cell surface-accessible epitope of a vesicular transporter protein on the surface of a neuronal cell, which transporter protein is transiently cell surface accessible,

wherein the immunotoxin, when contacted with a neuronal cell displaying the transporter protein on its surface, kills the neuronal cell.

2. The immunotoxin of claim 1 , wherein the cytotoxin is a ribosome-inactivating protein (RIP).

3. The immunotoxin of claim 2 , wherein the RIP is selected from the group consisting of a Type I RIP and a Type II RIP.

4. The immunotoxin of claim 2 , wherein the RIP is selected from the group consisting of saporin, luffin, momordins, ricin, and abrin.

5. The immunotoxin of claim 2 , wherein the RIP is saporin.

6. The immunotoxin of claim 1 , wherein the vesicular transporter protein is selected from the group consisting of a monoamine transporter, an acetylcholine transporter, a gamma-aminobutyric acid transporter, and a glutamate transporter.

7. The immunotoxin of claim 1 , wherein the neuronal cell is a cholinergic cell.

8. The immunotoxin of claim 1 , wherein the transporter protein is a vesicular acetylcholine transporter (VAChT).

9. The immunotoxin of claim 8 , wherein the antibody is an anti-VAChT monoclonal antibody.

10. The immunotoxin of claim 1 , wherein the cytotoxin molecule and antibody are covalently attached by reaction with 1-ethyl-3[3-dimethylaminopropyl] carbodiimide hydrochloride.

11. The immunotoxin of claim 1 , wherein the immunotoxin comprises at least 2 cytotoxin molecules per antibody molecule.

12. The immunotoxin of claim 1 , further comprising a detectable label.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 5, 2010
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024184/0792 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2002
From: CHALUPA, LEO M.; GUNHAN, EMINE; CHOUDARY, PRABHAKARA V.
To: REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE
Reel/Frame 013504/0035 →
Continuity (2)
Provisional Application 6030647200 · Jul 18, 2001
Related Publication 20060165705A1 · Jul 27, 2006